1. Home
  2. GGAL vs BLTE Comparison

GGAL vs BLTE Comparison

Compare GGAL & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grupo Financiero Galicia S.A.

GGAL

Grupo Financiero Galicia S.A.

HOLD

Current Price

$53.21

Market Cap

7.7B

Sector

Finance

ML Signal

HOLD

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$146.79

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GGAL
BLTE
Founded
1905
2018
Country
Argentina
United States
Employees
10079
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7B
6.2B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GGAL
BLTE
Price
$53.21
$146.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
7
Target Price
$69.00
$198.00
AVG Volume (30 Days)
1.6M
231.7K
Earning Date
03-07-2023
05-08-2026
Dividend Yield
3.70%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$62.29
N/A
Revenue Next Year
$22.88
$492.11
P/E Ratio
$13.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.89
$56.68
52 Week High
$62.11
$200.00

Technical Indicators

Market Signals
Indicator
GGAL
BLTE
Relative Strength Index (RSI) 59.18 53.71
Support Level $47.43 $148.00
Resistance Level $56.17 $151.41
Average True Range (ATR) 2.24 7.89
MACD 0.38 1.61
Stochastic Oscillator 56.69 85.97

Price Performance

Historical Comparison
GGAL
BLTE

About GGAL Grupo Financiero Galicia S.A.

Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. The company generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: